Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06180499
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-14
First Post:
2023-12-12
Brief Title:
Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ILDTreg2
Brief Summary:
Since the discovery that Treg suppress anti-tumor immune responses inhibiting their function has become a major challenge for the development of efficient immunotherapy for cancer In humans we previously reported the positive results of a first clinical trial using Treg depletion for anti-tumor response amplification in the field of allogeneic hematopoietic stem cell transplantation HSCT The present project aims at developing this anti-tumor immunotherapeutic strategy in the same setting ie donor lymphocyte infusion DLI for relapsing hematological malignancies after HSCT using a new selection marker CD127 The choice of this new strategy is supported by our results of a retrospective clinical study and pre-clinical data Using human cells this studies demonstrated in vitro and in vivo in animal murine models that Treg depletion through CD127 positive selection is much more efficient to improve allogeneic immune responses of donor T-cells as compared to the previous strategy using the CD25 marker
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None